hnk Search Results


hnk 1  (ATCC)
94
ATCC hnk 1
Hnk 1, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/HNK-1/pm12508228-186-37-45
Average 94 stars, based on 1 article reviews
hnk 1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
monoclonal antibody  (ATCC)
94
ATCC monoclonal antibody
Monoclonal Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/HNK-1/pm09924772-72-16-20
Average 94 stars, based on 1 article reviews
monoclonal antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd57apc vio770  (Miltenyi Biotec)
94
Miltenyi Biotec cd57apc vio770
Cd57apc Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/CD57+Antibody%2C+anti-human/pmc12992515-46-0-3
Average 94 stars, based on 1 article reviews
cd57apc vio770 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd57  (Proteintech)
93
Proteintech cd57
Cd57, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/CD57+Antibody/pm37759229-95-18-21
Average 93 stars, based on 1 article reviews
cd57 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
cd57 rea769 miltenyi biotech 130 124 525 t  (Miltenyi Biotec)
94
Miltenyi Biotec cd57 rea769 miltenyi biotech 130 124 525 t
Cd57 Rea769 Miltenyi Biotech 130 124 525 T, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/CD57+Antibody%2C+anti-human%2C+REAfinity/pmc12352894__jci-135-181034-s244-48-246-248
Average 94 stars, based on 1 article reviews
cd57 rea769 miltenyi biotech 130 124 525 t - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
rabbit anti phospho akt ser473  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc rabbit anti phospho akt ser473
Rabbit Anti Phospho Akt Ser473, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/CD57+(HNK-1)+Mouse+mAb/pmc08990169-57-34-39
Average 90 stars, based on 1 article reviews
rabbit anti phospho akt ser473 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
antibodies against cd3  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc antibodies against cd3
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Antibodies Against Cd3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/CD57+(HNK-1)+Mouse+mAb/pm38297019-246-31-35
Average 93 stars, based on 1 article reviews
antibodies against cd3 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
src activator tolimidone mlr 1023  (MedChemExpress)
94
MedChemExpress src activator tolimidone mlr 1023
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Src Activator Tolimidone Mlr 1023, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/(2S%2C6S)-Hydroxynorketamine+hydrochloride/pm42420382-98-18-23
Average 94 stars, based on 1 article reviews
src activator tolimidone mlr 1023 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
minisart syringe filter  (Sartorius AG)
94
Sartorius AG minisart syringe filter
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Minisart Syringe Filter, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/Minisart+Syringe+Filter+Polytetrafluorethylene/pmc12341388-56-18-21
Average 94 stars, based on 1 article reviews
minisart syringe filter - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
balance  (Sartorius AG)
98
Sartorius AG balance
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Balance, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/Cubis+II+Micro+and+Ultra-Micro+Configurable+Lab+Balances/10__1007_slash_s44274___024___00155___w-110-26-27
Average 98 stars, based on 1 article reviews
balance - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
incucyte zoom  (Sartorius AG)
99
Sartorius AG incucyte zoom
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Incucyte Zoom, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/Live+Cell+Analysis+Instruments/10__3892_slash_ol__2025__15433-76-10-12
Average 99 stars, based on 1 article reviews
incucyte zoom - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
hnk 1st reactions  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology hnk 1st reactions
Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF <t>[CD3</t> (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.
Hnk 1st Reactions, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnk/HNK-1ST+(h)-PR/pmc07673472-309-0-18
Average 92 stars, based on 1 article reviews
hnk 1st reactions - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

Image Search Results


Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF [CD3 (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.

Journal: NPJ precision oncology

Article Title: CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer.

doi: 10.1038/s41698-024-00513-0

Figure Lengend Snippet: Fig. 4 mIHC/IF-based quantification of CD57+CD8+ T cells predicts immunotherapeutic response in a retrospective NSCLC cohort (n = 90). a Representative images of NSCLC tissue stained using mIHC/IF [CD3 (green), CD8 (red), CD57 (pink), DAPI (blue)]. b mIHC/IF-based CD57+CD8+ T cells/T cells ratio (p < 0.001) and (c) CD57+CD8+ T cells/CD8+ T cells ratio (p < 0.001) predicted immunotherapeutic response in a retrospective NSCLC cohort (n = 90). d Total CD8+ T cells/T cells ratio by mIHC/IF was not of predictive value to immunotherapy (p = 0.679, n = 90). e Spearman’s rank correlation analysis was performed to compare the CD57+CD8+ T cells/T cells ratio (r = 0.644, p < 0.001), and f CD8+ T cells/T cells ratio (r = 0.346, p = 0.016) in blood and tumor samples (n = 48). ***p < 0.001. mIHC/IF multiplex immunohistochemistry/ immunofluorescence, NSCLC non-small cell lung cancer.

Article Snippet: Briefly, each FFPE tissue section was baked at 65 °C for 1 h. After deparaffinization, rehydration, and microwave antigen repair, the slides were blocked (Akoya Biosciences, USA), and incubated with primary antibodies against CD3 (D7A6E, CST, 85061 T, 1:200), CD57 (HNK-1, CST, 72031 S, 1:200), and CD8 (EPR22483-288, Abcam, ab245118, 1:500), respectively, followed by incubation with Opal Polymer HRP Ms+Rb (Akoya Biosciences, USA).

Techniques: Staining, Multiplex Assay, Immunohistochemistry